Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarMMa-3
2018-001023-38Phase 3Active
- Sponsor
- Celgene Corporation
- Start
- Jan 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of idecabtagene vicleucel in multiple myeloma (MM), sponsored by Celgene Corporation. Started Jan 2019; status: active.
02
Drugs
idecabtagene vicleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2018-001023-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001023-38.